ArticleAging2011
Molecular damage in cancer: an argument for mTOR-driven aging.
Article in Aging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysis.Oncotarget · 2016Pooled it
- The paradoxical activity of BRAF inhibitors: potential use in wound healing.Archives of dermatological research · 2025Review
- Review
- Does Aging Activate T-cells to Reduce Bone Mass and Quality?Current osteoporosis reports · 2022Review
- Hallmarks of cancer and hallmarks of aging.Aging · 2022Article
- Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.Cancer letters · 2021Article
- Paradoxes of senolytics.Aging · 2018Article
- Article
- Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway.Aging · 2017Article
- MicroRNAs and the metabolic hallmarks of aging.Molecular and cellular endocrinology · 2017Review
- From rapalogs to anti-aging formula.Oncotarget · 2017Review
- E-cigarettes and flavorings induce inflammatory and pro-senescence responses in oral epithelial cells and periodontal fibroblasts.Oncotarget · 2016Article
- Mitochondrial dysfunction and oxidative stress in aging and cancer.Oncotarget · 2016Review
- Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival.Oncotarget · 2016Article
- The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters.Oncotarget · 2016Observational
- Article
- Analysis of plasma microRNA expression profiles revealed different cancer susceptibility in healthy young adult smokers and middle-aged smokers.Oncotarget · 2016Article
- Stress resistance and lifespan are increased in C. elegans but decreased in S. cerevisiae by mafr-1/maf1 deletion.Oncotarget · 2016Article
- The Enigma of Rapamycin Dosage.Molecular cancer therapeutics · 2016Review
- When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?Current pharmacology reports · 2015Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite common belief, accumulation of molecular damage does not play a key role in aging. Still, cancer (an age-related disease) is initiated by molecular damage. Cancer and aging share a lot in common including the activation of the TOR pathway. But the role of molecular damage distinguishes cancer and aging. Furthermore, an analysis of the role of both damage and aging in cancer argues against "a decline, caused by accumulation of molecular damage" as a cause of aging. I also discuss how random molecular damage, via rounds of multiplication and selection, brings about non-random hallmarks of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.